Synthesis and Characterization of Mesoporous SBA-15 as Carriers to Improve the Rutin Dissolution Rate

Abstract

Background: Due to its low water solubility, Rutin, a crystalline medication used to treat a variety of conditions, has a limited rate of dissolution when given in gastrointestinal fluids. The present study planned to formulate and characterize Rutin using mesoporous silica material (SBA-15) as well as to determine the in-vitro dissolution properties. Methods: Rutin was formulated using mesoporous silica material such as SBA-15. Particle size distribution analysis, fourier transform-infrared (FT-IR) spectroscopy, scanning electron microscopy, and X-ray diffraction were used to characterize the compound in the complex. Rutins solubility and in-vitro release characteristics were assessed. Furthermore, the dissolution data (DD) Solver Excel add-in software was used to evaluate several mathematical models to interpret the Rutin dissolution kinetics from the mesoporous materials. Results: Differential scanning calorimetry was used to confirm Rutins amorphous state, which resulted in a significantly higher rate of dissolution than pure crystalline Rutin. The release of the drug from the Rutin/SBA-15 complex was well-simulated by the Weibull model. Notably, the SBA-15 carrier-mediated complex of Rutin exhibited the highest drug loading and dissolution rate, showing promising potential for enhancing Rutin bioavailability. Conclusion: The findings suggested that Rutin/SBA-15 could be easily incorporated into conventional oral pharmaceutical dosage forms such as capsules and therefore can be utilized for treating ailments such as allergies, inflammation, tumors, infections, protozoal diseases, and spasms. To assess the Rutin/SBA-15 complexs in-vivo pharmacokinetic performance and appropriateness for a range of pharmacological actions, more investigation is required.